Serum and urinary soluble α-Klotho levels in patients with chronic kidney disease
Keywords:chronic kidney disease, CDK, eGFR, soluble alpha-Klotho, urinary alpha-Klotho
Background: Chronic kidney disease is an epidemic global health problem that leads to death. To prevent any disease progression and treatment, the diagnosis must be made in the early stage by studying renal damage. Klotho is a protein found in many organs of the human body, but it is mainly abundant in the kidney.
Objectives: This study is aimed to evaluate klotho’s clinical significance as an additional biomarker for diagnosing chronic kidney disease in its early stages.
Methods: One hundred subjects were included in this study to measure their serum and urinary klotho. Forty patients with chronic kidney disease (pre-dialysis) and sixty normal subjects were enrolled in this study. Serum and urinary klotho were determined using the ELISA technique in addition to other renal function tests.
Results: Serum and urinary alpha klotho were decreased in CKD patients when compared with control subjects. A positive correlation was found between serum creatinine and urinary alpha klotho in the patients’ group.
Conclusion: Serum and urinary alpha klotho levels were decreased significantly in patients with chronic kidney disease compared with healthy controls.
Khodeir S, Okda H, Abdalal HM. Clinical significance of fibroblast growth factor-23 and soluble alpha klotho in different stages of chronic kidney disease. Saudi Journal of Kidney Diseases and Transplantation. 2019;30(1):108–118. Available from: https://dx.doi.org/10.4103/1319-2442.252900.
Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Fernandez-Fernandez B, Martin-Cleary C, et al. Clarifying the concept of chronic kidney disease for non-nephrologists. Clinical Kidney Journal. 2019;12(2):258–261. Available from: https://dx.doi.org/10.1093/ckj/sfz007.
Garland JS. Elevated body mass index as a risk factor for chronic kidney disease: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:347–355.
Picciotto D, Murugavel A, Ansaldo F, Rosa GM, Sofia A, Milanesi S, et al. The Organ Handling of Soluble Klotho in Humans. Kidney and Blood Pressure Research. 2019;44(4):715–726. Available from: https://dx.doi.org/10.1159/000501316.
Liu X, Niu Y, Zhang X, Zhang Y, Yu Y, Huang J, et al. Recombinant α-Klotho Protein Alleviated Acute Cardiorenal Injury in a Mouse Model of Lipopolysaccharide-Induced Septic Cardiorenal Syndrome Type 5. Analytical Cellular Pathology. 2019;2019. Available from: https://dx.doi.org/10.1155/2019/5853426.
Zhong X, Jagarlapudi S, Weng Y, Ly M, Rouse JC, McClure K, et al. Structurefunction relationships of the soluble form of the anti-aging protein Klotho have therapeutic implications for managing kidney disease. Journal of Biological Chemistry. 2020;295(10):3115–3133. Available from: https://dx.doi.org/10.1074/jbc.RA119.012144.
Kim JH, Hwang KH, Park KS, Kong ID, Cha SK. Biological role of anti-aging protein Klotho. Journal of Lifestyle Medicine . 2015;5(1):1–6. Available from: 10.15280/jlm.2015.5.1.1.
Sanchez-Niño MD, Fernandez-Fernandez B, Ortiz A. Klotho, the elusive kidneyderived anti-ageing factor . Clinical Kidney Journal. 2020;13(2):125–127. Available from: https://doi.org/10.1093/ckj/sfz125.
Liu QF, Yu LX, Feng JH, Sun Q, Li SS, Ye JM. The Prognostic Role of Klotho in Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis. Disease markers. 2019;2019(Article ID 6468729):1–12. Available from: https://doi.org/10.1155/2019/6468729.
Neyra JA, Hu MC. _Klotho and chronic kidney disease. In: Litwack G, et al., editors. Vitamins & Hormones . vol. 101. Academic Press; 2016. p. 257–310. Available from: https://doi.org/10.1016/bs.vh.2016.02.007.
Lu X, Hu MC. Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Diseases. 2017;3(1):15–23. Available from: https://doi.org/10.1159/000452880.
Seo MY, Yang J, Lee JY, Kim K, Kim SC, Chang H, et al. Renal Klotho expression in patients with acute kidney injury is associated with the severity of the injury. The Korean Journal of Internal Medicine. 2015;30(4):489. Available from: https://doi.org/10.3904/kjim.2015.30.4.489.
Lee EY, Kim SS, Lee JS, Kim IJ, Song SH, Cha SK, et al. Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes. PLoS One. 2014;9(8):e102984. Available from: https://doi.org/10.1371/journal.pone.0102984.
Tsai CW, Ting IW, Yeh HC, Kuo CC. Longitudinal change in estimated GFR among CKD patients: A 10-year follow-up study of an integrated kidney disease care program in Taiwan. PLoS One. 2017;12(4):e0173843. Available from: https://doi.org/10.1371/journal.pone.0173843.
Melsom T, Nair V, Schei J, Mariani L, Stefansson VTN, Harder JL, et al. Correlation Between Baseline GFR and Subsequent Change in GFR in Norwegian Adults Without Diabetes and in Pima Indians. American Journal of Kidney Diseases. 2019;73(6):777–785. Available from: https://doi.org/10.1053/j.ajkd.2018.11.011.
Kumaresan R, Giri P. A Comparison of Serum Cystatin C and Creatinine with Glomerular FiltrationRate in Indian Patients with Chronic Kidney Disease. Oman Medical Journal. 2011;26(6):421–425. Available from: https://dx.doi.org/10.5001/omj.2011.107.
Copyright (c) 2021 Khalid J. Al-Jewari, Rayah S. Baban, Jawad Kadhim Manuti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain all proprietary rights, including copyright, such as patent and trade mark rights and rights to any process or procedure described in the article.